CATIE

Government of Canada announces over $13 million to help address harms related to substance use in the Prairies, Northwest Territories and Yukon

Retrieved on: 
Wednesday, March 15, 2023
Addiction, Health Canada, Harm reduction, Drug, Dutch Association of Mental Health and Addiction Care, Substance, MB, Organization, HIV, Indigenous self-government in Canada, Government, Death, Friends, Stigma, Mental health, Federation, Language, CATIE, Pharmaceutical industry, Health, Prairie

The funding announced today will allow people living in the Prairies, Northwest Territories and Yukon to access greater prevention, harm reduction and treatment services including access to safer supply programs.

Key Points: 
  • The funding announced today will allow people living in the Prairies, Northwest Territories and Yukon to access greater prevention, harm reduction and treatment services including access to safer supply programs.
  • This includes people disproportionately affected by problematic substance use or who face barriers accessing services such as youth, equity-deserving, and 2SLGBTQIA+ individuals.
  • The Government of Canada continues to work closely with partners to provide a compassionate and evidence-based response to the crisis.
  • Our government is committed to reducing the stigma associated with substance use so that Canadians feel safe asking for help.

Levitee Labs Announces Strategic Partnership with LiveRx Research Group to Provide Equitable Access to Hepatitis C Care throughout Alberta, Canada

Retrieved on: 
Monday, December 20, 2021
Hepatitis B, Epidemiology, Technology, Pharmacy, OTC, Research, Pharmacist, Public Health Agency of Canada, American, USD, QC, Liver, Health system, LVT, Infection, FSE, Chronic pain, Spanish National Health System, Â, CATIE, Patient, Quality of life, Working group, Pharming, Hepatitis C, Program, University, APA, Prescription, GLOBE, Network, Division, Liver cancer, Hepatology, Partnership, CSE, HCV, Pharmaceutical industry, Hospital, Dietary supplement, Vaccine, Gastroenterology

The partnership involves Levitee Labs promoting and implementing the LiveRx test and treat program, providing HCV screening and treatment, in addition to communications on optimal care strategies through the Levitee Labs portfolio of companies.

Key Points: 
  • The partnership involves Levitee Labs promoting and implementing the LiveRx test and treat program, providing HCV screening and treatment, in addition to communications on optimal care strategies through the Levitee Labs portfolio of companies.
  • As part of the collaboration agreement, Levitee Labs will implement the LiveRx HCV test and treat program at its Levitee Clinics and Levitee Pharmacies across Alberta from January 2022 through January 2024.
  • Including patients identified with HCV who are within the Levitee Clinics care program as part of the LiveRx HCV eradication research program.
  • The project is focused on tackling the challenge of inequitable access to Hepatitis C Virus care in Alberta.